Dimai, Hans Peter

Fracture risk and zoledronic acid therapy in men with osteoporosis

Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine

Bone health and osteoporosis researchBone health and treatments

Cited by 359

Sclerostin and Its Association with Physical Activity, Age, Gender, Body Composition, and Bone Mineral Content in Healthy Adults

Amrein, K., Amrein, S., Drexler, C., Dimai, H. P., Dobnig, H., Pfeifer, K., Tomaschitz, A., Pieber, T. R., & Fahrleitner-Pammer, A. (2012) · The Journal of Clinical Endocrinology & Metabolism

Bone health and osteoporosis researchBone Metabolism and Diseases

Cited by 277

Long-term and sequential treatment for osteoporosis

Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology

Bone health and osteoporosis researchBone health and treatments

Cited by 273

Plasma parathyroid hormone and cardiovascular disease in treatment‐naive patients with primary hyperparathyroidism: The EPATH trial

Wetzel, J., Pilz, S., Grübler, M. R., Fahrleitner‐Pammer, A., Dimai, H. P., von Lewinski, D., Kolesnik, E., Perl, S., Trummer, C., Schwetz, V., et al. (2017) · The Journal of Clinical Hypertension

Parathyroid Disorders and TreatmentsHormonal Regulation and Hypertension

Cited by 22